Cyclic Glycine-Proline and Selank Interaction: Compatible | Peptide Database

Join others researching Dapoxetine — share findings, ask questions, and learn from real experiences Dapoxetine is the first and only selective serotonin reuptake inhibitor (SSRI) specifically developed and approved for the on-demand treatment of premature ejaculation (PE) in men aged 18-64. Unlike conventional SSRIs such as paroxetine or sertraline -- which are sometimes used off-label for PE but require daily dosing and weeks to reach therapeutic effect -- dapoxetine was engineered for rapid absorption and short elimination, making it suitable for as-needed use 1-3 hours before sexual activity. Originally developed by Eli Lilly and later licensed to Johnson & Johnson (ALZA Corporation), dapoxetine received its first regulatory approval in Sweden in 2009 under the brand name Priligy, and has since been approved in over 50 countries across Europe, Asia, Latin America, and the Middle East. It has not received FDA approval in the United States despite multiple submissions. Dapoxetine works by increasing serotonin activity at the postsynaptic cleft in the ejaculatory reflex pathway, raising the threshold for ejaculation and improving control over the timing of climax. Dapoxetine selectively inhibits the serotonin transporter (SERT) at presynaptic nerve terminals, blocking reuptake of serotonin (5-HT) from the synaptic cleft. This increases serotonin concentration at postsynaptic receptors in the neural circuits governing the ejaculatory reflex, particularly within the spinal ejaculation generator and supraspinal pathways. The ejaculatory process is modulated by serotonergic neurotransmission: higher serotonin levels at 5-HT1B and 5-HT2C receptors raise the ejaculatory threshold, delaying the emission and expulsion phases of ejaculation. Unlike traditional SSRIs that require 1-2 weeks of daily dosing to achieve steady-state serotonin levels, dapoxetine reaches peak plasma concentration within approximately 1-2 hours after oral administration and is rapidly eliminated (terminal half-life ~1.5 hours, with an initial half-life of ~1.4 hours). This pharmacokinetic profile enables acute, on-demand modulation of serotonergic tone without the sustained receptor desensitization seen with chronic SSRI use.

Join others researching Bronchogen — share findings, ask questions, and learn from real experiences Bronchogen is a Khavinson bioregulator tetrapeptide (AEDL) with primary effects on the bronchopulmonary system. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson, it targets bronchial tissue and supports respiratory function. Like other Khavinson peptides, Bronchogen penetrates cell nuclei to influence gene expression related to respiratory tissue maintenance and repair. Bronchogen works through epigenetic regulation by penetrating cell and nuclear membranes to interact with DNA and modulate gene expression in bronchial tissue. It regulates protein synthesis in bronchopulmonary cells, supporting maintenance and repair of respiratory epithelium. The tetrapeptide structure allows efficient cellular uptake and tissue-specific targeting to bronchial structures.